Get the Stockscreener App
0.8201
0.99%
-0.0082
Filana Therapeutics Inc stock is traded at $0.8201, with a volume of 285.23K.
It is down -0.99% in the last 24 hours and down -17.69% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$0.8283
Open:
$0.82
24h Volume:
285.23K
Relative Volume:
0.82
Market Cap:
$39.62M
Revenue:
-
Net Income/Loss:
$-77.90M
P/E Ratio:
-0.5085
EPS:
-1.6127
Net Cash Flow:
$-30.38M
1W Performance:
-11.72%
1M Performance:
-17.69%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.802
$0.847
1-Week Range:
$0.802
$0.93
52-Week Range:
$0.802
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
0.8201 | 45.53M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
Filana (FLNA) Earnings Snapshot: The EPS Result Is Above Expectation in Latest Trading; After Results: The Market Price Declines 3.72% for the Current SessionMargin Compression Risk - vinanet.vn
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - Kalkine
Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071 - marketscreener.com
Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling - TipRanks
Law firm investigates Filana Therapeutics officers for possible shareholder rights breaches - Pluang
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates by 20.12% as Shares Dip 2.58%Earnings Manipulation Risk - vinanet.vn
FLNA Q3 2025 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Per Share - vinanet.vn
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Volatility Smile - dars.gov.et
Filana Therapeutics (FLNA) Slides 3.3% to $1.00 as Small-Cap Biotech Approaches Key SupportRisk Reversal - vinanet.vn
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.21%Low Estimate Range - vinanet.vn
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update - GlobeNewswire
Filana Therapeutics Q2 EPS beats estimate, loss narrows 81% - scanx.trade
Filana Therapeutics Faces Pressure as Shares Slide 4.43%Support at $0.85 in FocusIV Spike - vinanet.vn
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA - TradingView
Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in FocusATR Stop - dars.gov.et
MSN Money - MSN
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideEPS Surprise History - dars.gov.et
Filana Therapeutics (FLNA) Surges 4.8% as Biotech Momentum BuildsBPI Bear Correction - dars.gov.et
FLNAFilana Therapeutics Inc Short Interest - Finviz
FLNA Should I Buy - Intellectia AI
Price to sales forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to book forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (NASDAQ:FLNA) - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (TRADEGATE:PX91) - TradingView
Enterprise value to revenue forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to earnings forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Filana Therapeutics (FLNA) Holds Near Support Amid Modest DeclinePrice Surge Stocks - dars.gov.et
Filana Therapeutics Shareholders Back Board, Compensation Plans - The Globe and Mail
FLNA Q3 2025 Earnings: Narrower Loss Beats Street, But Shares Slide on UncertaintyLow Estimate Range - newsline.com
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Trend Analysis - newsline.com
Filana Therapeutics, Inc. 8-K Filing Details: Amended 2018 Omnibus Incentive Plan and Company Information (June 2026) – Minichart - Minichart
Filana Therapeutics (FLNA) investors back directors, plan changes and auditor - Stock Titan
Filana Therapeutics (FLNA) Slips 4.6% as Biotech Sector Headwinds Test SupportConversion Trade - newsline.com
FLNA: All proposals passed as the company focuses on resolving the FDA clinical hold for its TSC program - TradingView
Filana Therapeutics (FLNA) Surges Over 8%—Testing Key Resistance at $1.50Beta Neutral Pair - newsline.com
Filana Therapeutics (FLNA) Edges Higher as Stock Tests Key Resistance LevelTrend Following Picks - newsline.com
Filana Therapeutics (FLNA) Slips 4.5% as Stock Approaches Key Support LevelIV Rank - newsline.com
Data I/O And 2 Other Promising Penny Stocks To Watch - simplywall.st
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock RallyEarnings Surprise Stocks - The Legal Advocate
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Propels Shares HigherEarnings Volatility Report - dars.gov.et
Filana Therapeutics (FLNA) Gains 6.38% as Biotech Momentum BuildsPCR Spike - newsline.com
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.0 - GuruFocus
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.00 - GuruFocus
Filana Therapeutics (FLNA) Posts Modest Gains Amid Broader Biotech ResilienceExpert Breakout Alerts - Newser
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Filana Therapeutics Inc Stock (FLNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):